Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS 22 3-Year RORE % is 61.22 as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 944 Drug Manufacturers companies, Curis Lifesciences ranks better than 85.59% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Curis Lifesciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was 61.22%.
The industry rank for Curis Lifesciences's 3-Year RORE % or its related term are showing as below:
NSE:CURIS's 3-Year RORE % is ranked better than 85.59% of 944
companies
in the Drug Manufacturers industry
Industry Median: 2.82
vs NSE:CURIS: 61.22
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Curis Lifesciences 3-Year RORE % Related Terms
Curis Lifesciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences 3-Year RORE % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
3-Year RORE %
0.00
0.00
33.45
61.22
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
3-Year RORE %
0.00
0.00
33.45
61.22
NSE:CURIS vs ZTS: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Curis Lifesciences (NSE:CURIS) has a 3-Year RORE % of 61.22 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Curis Lifesciences and its competitors. According to the industry distribution chart, Curis Lifesciences ranks #136 out of 944 companies in the Drug Manufacturers industry, placing it in the top 14.4%.
Is Curis Lifesciences' 3-Year RORE % too high?
Curis Lifesciences' current 3-Year RORE % is 61.22. The Drug Manufacturers industry median 3-Year RORE % is 2.82. Curis Lifesciences' value of 61.22 is 2070.9% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #136 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #136 out of 944 companies for 3-Year RORE %. This places Curis Lifesciences in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 2.82. Curis Lifesciences' value of 61.22 is 2070.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.82, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current 3-Year RORE % of 61.22 is 2070.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current 3-Year RORE % is 61.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current 3-Year RORE % of 61.22. The current 3-Year RORE % is 61.22 and 2070.9% above the Drug Manufacturers industry median of 2.82. Curis Lifesciences' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current 3-Year RORE % is 61.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
22GF Score
Get the complete analysis for NSE:CURIS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
